John de Kruif
Chief Tech/Sci/R&D Officer en MERUS N.V. .
Perfil
John de Kruif is currently the Chief Technology Officer & Senior Vice President at Merus NV since 2013.
Prior to his current position, he worked as the Director-Antibody Discovery at Crucell NV from 2000 to 2006.
Dr. de Kruif holds a doctorate degree from the University of Utrecht.
Cargos activos de John de Kruif
| Empresas | Cargo | Inicio |
|---|---|---|
| MERUS N.V. | Chief Tech/Sci/R&D Officer | 01/04/2007 |
Antiguos cargos conocidos de John de Kruif.
| Empresas | Cargo | Fin |
|---|---|---|
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Corporate Officer/Principal | 01/10/2006 |
Formación de John de Kruif.
| University of Utrecht | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| MERUS N.V. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |
- Bolsa de valores
- Insiders
- John de Kruif
